Clinical Trial

A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Study acronym: EVOLVE-2
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-12-04; most recent amendment 2026-06-01.
Status change: Recruiting → Active, Not Recruiting 2026-03-17
Trial Details
NCT Number NCT07281937
Lead Sponsor Verdiva Bio Dev Limited
Conditions Obesity, Overweight
Enrollment 206 participants
Start Date 2025-11-25
Primary Completion 2026-07 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-03